Hantavirus infectious disease
disease diseaseOn this page
Also known as disease due to hantavirusHantavirus caused disease or disorderHantavirus disease or disorderHantavirus infectioninfections, Hantavirus
Summary
Hantavirus infectious disease (MONDO:0005780) is a disease and 5 clinical trials. Top therapeutic interventions include methylprednisolone. A subtype of Bunyaviridae infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 5
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | hantavirus infectious disease |
| Mondo ID | MONDO:0005780 |
| EFO | EFO:0007295 |
| MeSH | D018778 |
| NCIT | C3899 |
| SNOMED CT | 359761005 |
| UMLS | C0242994 |
| MedGen | 67028 |
| Is cancer (heuristic) | no |
Also known as: disease due to hantavirus · Hantavirus caused disease or disorder · Hantavirus disease or disorder · Hantavirus infection · Hantavirus infectious disease · infections, Hantavirus
Disease family
An umbrella term covering 2 Mondo subtypes.
Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › viral infectious disease › primary viral infectious disease › Bunyaviridae infectious disease › hantavirus infectious disease
Related subtypes (2): Oropouche fever, la Crosse encephalitis
Subtypes (2): hantavirus hemorrhagic fever with renal syndrome, hantavirus pulmonary syndrome
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated or in trials for this disease
No drug has an approved disease-direct ChEMBL indication for this disease.
1 drug in clinical trials for this disease (phase 2–3, investigational): efficacy not established — a trial record, not an indication.
| Drug | Highest phase |
|---|---|
| Methylprednisolone | Phase 2 |
Clinical trials & evidence
Clinical trials
Clinical trials: 5.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 4 |
| PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00128180 | PHASE2 | COMPLETED | Efficacy of Methylprednisolone for Hantavirus Cardiopulmonary Syndrome |
| NCT04323904 | Not specified | RECRUITING | Hantavirus Registry - HantaReg |
| NCT07358910 | Not specified | RECRUITING | Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective |
| NCT00533767 | Not specified | TERMINATED | Hantavirus Transmission in Households in Chile |
| NCT05415904 | Not specified | COMPLETED | Hantavirus Nephropathy in North-Eastern France : Severity Risk Factors and Prognostic Tools |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| METHYLPREDNISOLONE | 4 | 1 |
Related Atlas pages
- Drugs: Methylprednisolone